Expression of WISP3 and RhoC genes at mRNA and protein levels in inflammatory and noninflammatory breast Cancer in Tunisian patients

Cancer Investigation

Volumn 28, Issue 4, 2010, Pages 399-407

  Marrakchi, Raja ^a   Khadimallah, Ines ^a   Ouerhani, Slah ^a   Gamoudi, Amor ^b   Khomsi, Fathi ^b   Bouzaine, Hatem ^b   Benamor, Mohamed ^a   Bougatef, Karim ^a   Mnif, Samia ^c   Zitoun, Rayhana ^a   Benna, Farouk ^b   Boussen, Hammouda ^b   Rahal, Khaled ^b   Elgaaied, Amel Benammar ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b SALAH AZAIEZ INSTITUTE   (Tunisia)

^c PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

Immunohistochemistry; Inflammatory breast cancer; RhoC; RT PCR; Tunisian population; WISP3

Indexed keywords

MESSENGER RNA; PROTEIN; PROTEIN RHOC; PROTEIN WISP3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTITIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHOC GENE; TUNISIA; WISP3 GENE;

EID: 77950559446     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900903405926     Document Type: Article

References (41)

1. Chevallier, B.; Asselain, B.; Kunlin, A.; Veyret, C.; Bastit, P.; Graic, Y. Inflammatory breast cancer: determination of prognostic factors by univariate and multivariate analysis. Cancer 1987, 60, 897-902.
2. Boussen, H.; Bouzaine, H.; Ben Hassouna, J.; Gammoudi, A.; Benna, F.; Rahal, K. Inflammatory breast cancer in Tunisia: reassessment of incidence and linicopathological features. Seminars Oncologie 2008, 35, 17-24.
3. Chang, S.; Parker, S.L.; Pham, T.; Buzdar, A.U.; Hursting, S.D. Inflammatory breast carcinoma: incidence and survival. The surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 1998, 82, 2366-2372.
4. Van dA, I.; Van Laere, S.J.; Van den Eynden, G.G.; Benoy, I.; van Dam, P.; Colpaert, C.G.; Fox, S.B.; Turley, H.; Harris, A.L.; Van Marck, E.A.; Vermeulen, P.B.; Dirix, L.Y. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004, 10, 7965-7971.
5. Cristofanilli, M.; Buzdar, A.U.; Hortobagyi, G.N. Update on the management of inflammatory breast cancer. Oncologist 2003, 8, 141-148.
6. Jaiyesimi, I.A.; Buzdar, A.U.; Hortobagyi, G. Inflammatory breast cancer: a review. J Clin Oncol 1992, 10, 1014-1024.
7. Swain, S.M.; Sorace, R.A.; Bagley, C.S.; Danforth, D.N., Jr.; Bader, J.; Wesley, M.N.; Steinberg, S.M.; Lippman, M.E. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987, 47, 3889-3894.
8. Levine, P.H.; Steinhorn, S.C.; Ries, L.G.; Aron, J.L. Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 1985, 74, 291-297.
9. Levine, P.H.; Pogo, B.G.; Klouj, A.; Coronel, S.; Woodson, K.; Melana, S.M.; Mourali, N.; Holland, J.F. Increasing evidence for a human breast carcinoma virus with geographic differences. Cancer 2004, 101, 721-726.
10. Mourali, N.; Levine, P.H.; Tabanne, F.; Belhassen, S.; Bahi, J.; Bennaceur, M.; Herberman, R.B. Rapidly progressing breast cancer (poussee evolutive) in Tunisia: studies on delayed hypersensitivity. Int J Cancer 1978, 22, 1-3.
11. Charafe-Jauffret, E.; Tarpin, C.; Bardou, V.J.; Bertucci, F.; Ginestier, C.; Braud, A.C.; Puig, B.; Geneix, J.; Hassoun, J.; Birnbaum, D.; Jacquemier, J.; Viens, P. Immunophenotypic analysis of inflammatory breast cancers: identification of an inflammatory signature. J Pathol 2004, 202, 265-273. (Pubitemid 38325235)
12. Charafe-Jauffret, E.; Mrad, K.; Intidhar, L.S.; Ben Hamida, A.; Ben Romdhane, K.; Ben Abdallah, M.; Ginestier, C.; Esterni, B.; Birnbaum, D.; Ben Ayed, F.; Xerri, L.; Viens, P.; Mezlini, A.; Jacquemier, J. Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast 2007, 16, 352-358.
13. Kleer, C.G.; Zhang, Y.; Pan, Q.; Gallagher, G.; Wu, M.; Wu, Z.F.; Merajver, S.D. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 2004, 6(2), 110-115.
14. Kleer, C.G.; van Golen, K.L.; Zhang, Y.; Wu, Z.F.; Rubin, M.A.; Merajver, S.D. Characterization of RhoC expression in benign and malignant breast disease. Am J Pathol 2002, 160, 579-584.
15. Kimura, K.; Ito, M.; Amano, M.; Chihara, K.; Fukata, Y.; Nakafuku, M.; Yamamori, B.; Feng, J.; Nakano, T.; Okawa, K.; Iwamatsu, A.; Kaibuchi, K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996, 273, 245-248.
16. Nobes, C.D.; Hall, A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995, 81, 53-62.
17. Jaffe, A.B.; Hall, A. RHO GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005, 21, 247-269.
18. Watanabe, T.; Noritake, J.; Kaibuchi, K. Regulation ofmicrotubules in cell migration. Trends Cell Biol 2005, 15, 76-83.
19. Wheeler, A.P.; Ridley, A.J. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res 2004, 301, 43-49.
20. Ridley, A.J. Rho proteins and cancer. Breast Cancer Res Treat 2004, 84, 13-19.
21. Wu, M.; Wu, Z.F.; Kumar-Sinha, C.; Chinnaiyan, A.; Merajver, S.D. RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat 2004, 84, 3-12. (Pubitemid 38388855)
22. Perbal, B. NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 2001, 54, 57-79. (Pubitemid 32269998)
23. Hurvitz, J.R.; Suwairi, W.M.; Van Hul, W.; El-Shanti, H.; Superti- Furga, A.; Roudier, J.; Holderbaum, D.; Pauli, R.M.; Herd, J.K.; Van Hul, E.V.; Rezai- Delui, H.; Legius, E.; Le Merrer, M.; Al-Alami, J.; Bahabri, S.A.; Warman, M.L. Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia. Nat Genet 1999, 23, 94-98. (Pubitemid 29418796)
24. Moussad, E.E.; Brigstock, D.R. Connective tissue growth factor: what's in a name? Mol Genet Metab 2000, 71, 276-292.
25. Bringstock, D. The CCN family: a new stimulus package. J Endocrinol 2003, 178, 169-175.
26. Sen, M.; Cheng, Y-H.; Goldring, M.B.; Lotz, M.K.; Carson, D.A. WISP-3 dependent regulation of type II collagen and aggrecan production in chondrocytes. Arthritis Rheum 2004, 50, 488-497. (Pubitemid 38198833)
27. Davis, L.; Chen, Y.; Sen, M. WISP-3 functions as a ligand and promotes superoxide dismutase activity. BBRC 2006, 342, 259-265. (Pubitemid 43247385)
28. Kleer, C.G.; Zhang, Y.; Pan, Q.; van Golen, K.L.; Wu, Z.F.; Livant, D.; Merajver, S.D. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 2002, 21, 3172-3180. (Pubitemid 34552242)
29. Lamb, R.; Thomson, W.; Ogilvie, E.; Donn, R. Wnt-1 inducible signaling pathway protein 3 and susceptibility to juvenile idiopathic arthritis. Arthritis Rheum 2005, 52, 3548-3553.
30. van Golen, K.L.; Davies, S.; Wu, Z.F.; Wang, Y.; Bucana, C.D.; Root, H.; Chandrasekharappa, S.; Strawderman, M.; Ethier, S.P.; Merajver, S.D. A novel putative low affinity insulin-like growth factor binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999, 5, 2511-2519. (Pubitemid 29437336)
31. Cervello, M.; Giannitrapani, L.; Labbozzetta, M.; Notarbartolo, M.; D'Alessandro, N.; Lampiasi, N.; Azzolina, A.; Montalto, G. Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann N Y Acad Sci 2004, 1028, 432-439. (Pubitemid 40361844)
32. Pennica, D.; Swanson, T.A.; Welsh, J.W.; Roy, M.A.; Lawrence, D.A.; Lee, J.; Brush, J.; Taneyhill, L.A.; Deuel, B.; Lew, M.; Watanabe, C.; Cohen, R.L.; Melhem, M.F.; Finley, G.G.; Quirke, P.; Goddard, A.D.; Hillan, K.J.; Gurney, A.L.; Botstein, D.; Levine, A.J. WISP genes are members of the connective tissue growth factor family that are upregulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA 1998, 95, 14717-14722. (Pubitemid 29003696)
33. van Golen, K.L.; Wu, Z.F.; Qiao, X.T.; Bao, L.W.; Mearajver, S.D. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000, 60, 5832-5838.
34. Van den Eynden, G.G.; Van der Auwera, I.; Van Laere, S.; Colpaert, C.G.; van Dam, P.; Merajver, S.; Kleer, C.G.; Harris, A.L.; Van Marck, E.A.; Dirix, L.Y.; Vermeulen, P.B. Validation of a tissue microarray to study differential protein expression in inflammatory and noninflammatory breast cancer. Breast Cancer Res Treat 2004, 85, 13-22. (Pubitemid 38437979)
35. Kamai, T.; Tsujii, T.; Arai, K.; Takagi, K.; Asami, H.; Ito, Y.; Oshima, H. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003, 9(7), 2632-2641. (Pubitemid 36842107)
36. Horiuchi, A.; Itoh, K.; Shimizu, M.; Nakai, I.; Yamazaki, T.; Kimura, K.; Suzuki, A.; Shiozawa, I.; Ueda, N.; Konishi, I. Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol Oncol 2003, 88(3), 309-317. (Pubitemid 36331983)
37. Suwa, H.; Oshio, G.; Imamura, T.; Watanabe, G.; Arii, S.; Imamura, M.; Hiai, H.; Fukumoto, M. Overexpression of the RhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998, 77, 147-152. (Pubitemid 28029787)
38. Clark, E.A.; Golub, T.R.; Lander, E.S.; Hynes, R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2002, 406, 532-535.
39. Sahai, E.; Marshall, C.J. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 2002, 4, 408-415. (Pubitemid 34746158)
40. Sawaki, M.; Ito, Y.; Akiyama, F.; Tokudome, N.; Horii, R.; Mizunuma, N.; Takahashi, S.; Horikoshi, N.; Imai, T.; Nakao, A.; Kasumi, F.; Sakamoto, G.; Hatake, K. High Prevalence of HER- 2/neu and p53 Overexpression in Inflammatory Breast Cancer. Breast Cancer 2006, 13, 172-178.
41. Bertheau, I.; Plassa, F.; Espí e, M.; Turpin, E.; de Roquancourt, A.; Marty, M.; Lerebours, F.; Beuzard, Y.; Janin, A.; de Th́ e, H. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002, 360, 852-854. (Pubitemid 35257951)